Novartis
830.45
-19.10(-2.25%)
Market Cap₹2,050.44 Cr
PE Ratio21.57
IndustryHealthcare
Company Performance:
1D-2.25%
1M+3.58%
6M-10.98%
1Y+3.23%
5Y+34.47%
View Company Insightsright
More news about Novartis
09May 25
Novartis India Reports Robust Q4 Results, Declares ₹25 Dividend
Novartis India Limited has released its Q4 financial results, showing significant improvements across key metrics. Revenue increased by 3.36% to ₹839.00 crore. EBITDA more than doubled to ₹239.00 crore, with the EBITDA margin expanding to 28.49%. Net profit surged by 99.59% to ₹293.00 crore. The company's board has recommended a dividend of ₹25.00 per equity share.
 no imag found
Novartis
830.45
-19.10
(-2.25%)
1 Year Returns:+3.23%
Industry Peers
Sun Pharmaceutical
1,713.40
(-0.64%)
Divis Laboratories
6,297.50
(+0.22%)
Torrent Pharmaceuticals
4,226.40
(+0.37%)
Cipla
1,328.90
(-1.55%)
Dr Reddys Laboratories
1,282.30
(+0.16%)
Lupin
2,228.70
(+0.09%)
Zydus Life Science
902.40
(-0.84%)
Mankind Pharma
2,039.50
(-1.74%)
Aurobindo Pharma
1,171.40
(+1.02%)
Alkem Laboratories
5,377.00
(-1.59%)